Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience

202119 citationsJournal Articlegold Open Access

Authors

Akshee Batra · University of Vermont Medical Center

Brijesh Patel · West Virginia University

Daniel Addison · The Ohio State University Wexner Medical Center

Lauren A. Baldassarre · Yale University

Nihar R. Desai · Yale University

Neal L. Weintraub · Augusta University

Anita Deswal

Abstract

Antimicrotubular agents are associated with CVAEs, especially in combination chemotherapy regimens. Based on this study, we suggest routine cardiovascular assessment of patients with cancer before initiating antimicrotubular agents in combination therapy.

Topics & Keywords

Cancer Treatment and Pharmacology Chemotherapy-induced cardiotoxicity and mitigation Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Open Heart

Volume 8, Issue 2, pp. e001849-e001849

DOI: 10.1136/openhrt-2021-001849

Field-Weighted Citation Impact: 0.98